PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis.
暂无分享,去创建一个
[1] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[2] A. Kenny,et al. The short term effects of tamoxifen on bone turnover in older women. , 1995, The Journal of clinical endocrinology and metabolism.
[3] B. Adams-Huet,et al. Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial , 1995, Annals of Internal Medicine.
[4] R. Recker,et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] S. Cummings,et al. Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.
[6] B. Lanske,et al. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death , 1995, Molecular and cellular biology.
[7] S. Nagataki,et al. Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.
[8] J. Reginster,et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. , 1995, The American journal of medicine.
[9] E. Siris,et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.
[10] E. Siris,et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.
[11] G. Segre,et al. Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. , 1995, Endocrinology.
[12] A. Klibanski,et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. , 1994, The New England journal of medicine.
[13] J Glowacki,et al. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. , 1994, Genes & development.
[14] J. Orloff,et al. Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. , 1994, Endocrine reviews.
[15] R. Lindsay,et al. Anabolic actions of parathyroid hormone on bone. , 1993, Endocrine reviews.
[16] B. Riggs,et al. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. , 1993, The Journal of clinical endocrinology and metabolism.
[17] O. Tørring,et al. Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in rats , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] J. Nordenström,et al. Bone mineral density in patients with chronic hypoparathyroidism. , 1993, The Journal of clinical endocrinology and metabolism.
[19] Truls Østbye,et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. , 1993, The Journal of clinical investigation.
[20] A. F. Stewart,et al. Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell types. , 1992, The Journal of biological chemistry.
[21] G. Hendy,et al. A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. , 1992, The Journal of clinical endocrinology and metabolism.
[22] R. Lindsay,et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] J. Hock,et al. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] R. Lindsay,et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. , 1990, The Journal of clinical endocrinology and metabolism.
[25] T. Martin,et al. Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. , 1989, Endocrinology.
[26] T. Clemens,et al. Skeletal disease in primary hyperparathyroidism , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] M. Kleerekoper,et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. , 1988, Annals of internal medicine.
[28] A. F. Stewart,et al. Humoral hypercalcemia of malignancy. , 1988, Annals of Internal Medicine.
[29] L. Klenerman,et al. ANABOLIC EFFECT OF LOW DOSES OF A FRAGMENT OF HUMAN PARATHYROID HORMONE ON THE SKELETON IN POSTMENOPAUSAL OSTEOPOROSIS , 1976, The Lancet.
[30] P. Astrup,et al. The acid-base metabolism. A new approach. , 1960, Lancet.
[31] A. F. Stewart,et al. Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. , 1996, The Journal of clinical endocrinology and metabolism.
[32] S. Ljunghall,et al. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. , 1996, The Journal of clinical endocrinology and metabolism.
[33] R. Marier,et al. Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. , 1995, The Journal of clinical endocrinology and metabolism.